BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 11466586)

  • 1. Effect of IGF-I administration on growth hormone secretion in obese subjects.
    Tassone F; Gianotti L; Lanfranco F; Ganzaroli C; Oleandri SE; Taliano M; Muller EE; Ghigo E; Maccario M
    Int J Obes Relat Metab Disord; 2001 May; 25 Suppl 1():S41-2. PubMed ID: 11466586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of 36 hour fasting on GH/IGF-I axis and metabolic parameters in patients with simple obesity. Comparison with normal subjects and hypopituitary patients with severe GH deficiency.
    Maccario M; Aimaretti G; Grottoli S; Gauna C; Tassone F; Corneli G; Rossetto R; Wu Z; Strasburger CJ; Ghigo E
    Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1233-9. PubMed ID: 11477509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L; Maccario M; Lanfranco F; Ramunni J; Di Vito L; Grottoli S; Muller EE; Ghigo E; Arvat E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin infusion withdrawal: studies in the acute and recovery phase of anorexia nervosa, and in obesity.
    Pincelli AI; Rigamonti AE; Scacchi M; Cella SG; Cappa M; Cavagnini F; Müller EE
    Eur J Endocrinol; 2003 Feb; 148(2):237-43. PubMed ID: 12590644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M; Invitti C; Maccario M; Grottoli S; Cavagnini F; Camanni F; Ghigo E
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state.
    Broglio F; Gianotti L; Destefanis S; Fassino S; Abbate Daga G; Mondelli V; Lanfranco F; Gottero C; Gauna C; Hofland L; Van der Lely AJ; Ghigo E
    Clin Endocrinol (Oxf); 2004 May; 60(5):592-9. PubMed ID: 15104562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion.
    Grottoli S; Procopio M; Maccario M; Zini M; Oleandri SE; Tassone F; Valcavi R; Ghigo E
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2261-5. PubMed ID: 9215304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of recombinant human insulin-like growth factor I administration on spontaneous and growth hormone (GH)-releasing hormone-stimulated GH secretion in anorexia nervosa.
    Gianotti L; Pincelli AI; Scacchi M; Rolla M; Bellitti D; Arvat E; Lanfranco F; Torsello A; Ghigo E; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2805-9. PubMed ID: 10946886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome.
    Grugni G; Marzullo P; Ragusa L; Sartorio A; Trifirò G; Liuzzi A; Crinò A;
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):492-9. PubMed ID: 16984242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of beta-adrenergic agonists and antagonists on the growth hormone response to growth hormone-releasing hormone in anorexia nervosa.
    Gianotti L; Arvat E; Valetto MR; Ramunni J; Di Vito L; Maccagno B; Camanni F; Ghigo E
    Biol Psychiatry; 1998 Feb; 43(3):181-7. PubMed ID: 9494699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
    Panminerva Med; 1998 Mar; 40(1):13-7. PubMed ID: 9573747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans.
    Gianotti L; Ramunni J; Lanfranco F; Maccagno B; Giordano R; Broglio F; Maccario M; Muller EE; Ghigo E; Arvat E
    J Endocrinol Invest; 2001 Feb; 24(2):67-71. PubMed ID: 11263473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients.
    Alvarez-Castro P; Isidro ML; Garcia-Buela J; Leal-Cerro A; Broglio F; Tassone F; Ghigo E; Dieguez C; Casanueva FF; Cordido F
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):250-5. PubMed ID: 15272922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of somatostatin infusion on the somatotrope responsiveness to growth hormone-releasing hormone in patients with anorexia nervosa.
    Gianotti L; Rolla M; Arvat E; Belliti D; Valetto MR; Ferdeghini M; Ghigo E; Müller EE
    Biol Psychiatry; 1999 Feb; 45(3):334-9. PubMed ID: 10023511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased GH secretion in scrapie, a prion-associated neurodegenerative disease, is not due to suppressed IGF-1 negative feedback.
    Viguié C; Picard-Hagen N; Gayrard V; Toutain PL
    Domest Anim Endocrinol; 2009 Apr; 36(3):127-37. PubMed ID: 19179038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
    Minerva Endocrinol; 1999; 24(3-4):107-11. PubMed ID: 10953725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repetitive GHRH administration fails to increase the response to GHRH in obese subjects. Evidence for a somatotrope defect in obesity?
    Ghigo E; Procopio M; Maccario M; Bellone J; Arvat E; Campana S; Boghen MF; Camanni F
    Horm Metab Res; 1993 Jun; 25(6):305-8. PubMed ID: 8344645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of obesity and morbid obesity on the growth hormone (GH) secretion elicited by the combined GHRH + GHRP-6 test.
    Kelestimur F; Popovic V; Leal A; Van Dam PS; Torres E; Perez Mendez LF; Greenman Y; Koppeschaar HP; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):667-71. PubMed ID: 16712669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.